The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
School of Rehabilitation Sciences, Southern Medical University, Guangzhou, China.
Front Immunol. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235. eCollection 2022.
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic landscape of haematological malignancies. However, resistance and relapse remain prominent limitations, and they are related to the limited persistence and efficacy of CAR T cells, downregulation or loss of tumour antigens, intrinsic resistance of tumours to death signalling, and immune suppressive microenvironment. Rational combined modality treatments are regarded as a promising strategy to further unlock the antitumor potential of CAR T cell therapy, which can be applied before CAR T cell infusion as a conditioning regimen or in culture settings as well as concomitant with or after CAR T cell infusion. In this review, we summarize the combinatorial strategies, including chemotherapy, radiotherapy, haematopoietic stem cell transplantation, targeted therapies and other immunotherapies, in an effort to further enhance the effectiveness of this impressive therapy and benefit more patients.
嵌合抗原受体 (CAR) T 细胞疗法彻底改变了血液系统恶性肿瘤的治疗格局。然而，耐药和复发仍然是突出的限制因素，这与 CAR T 细胞的持久性和疗效有限、肿瘤抗原的下调或丢失、肿瘤对死亡信号的固有抵抗以及免疫抑制微环境有关。合理的联合治疗方法被认为是进一步挖掘 CAR T 细胞疗法抗肿瘤潜力的有前途的策略，可以在 CAR T 细胞输注前作为预处理方案，也可以在 CAR T 细胞培养环境中，以及与 CAR T 细胞输注同时或之后应用。在这篇综述中，我们总结了联合治疗策略，包括化疗、放疗、造血干细胞移植、靶向治疗和其他免疫疗法，以努力进一步提高这种令人印象深刻的治疗方法的效果，使更多的患者受益。
